BNT162b2 (COMIRNATY)

BLA STN 125742/0

Response to CBER 26 July 2021 Information Request Regarding Disposition of Participants in Safety Populations Who Experienced Pregnancy

July 2021

LIST OF ABBREVIATIONS

Abbreviation	Term
BLA	Biologics License Application
CBER	Center for Biologics Evaluation and Research
COVID-19	coronavirus disease 2019
CRF	Case report form
EDP	Exposure during pregnancy
FDA	Food and Drug Administration
LMP	Last menstrual period
mRNA	messenger ribonucleic acid
OVRR	Office of Vaccines Research and Review
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2

1. INTRODUCTION

Reference is made to BLA STN 125742/0 for COVID-19 mRNA Vaccine (COMIRNATY), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age and to CBER's 26 July 2021 Information Request received via email from Laura Gottschalk, PhD, CBER, OVRR regarding the disposition of participants in safety populations who experienced pregnancy.

CBER's request in ***bold italics*** is followed by Pfizer/BioNTech's response below.

2. CBER REQUEST AND PFIZER/BIONTECH'S RESPONSE

CBER Request

The review team has comments for you regarding the disposition of participants in safety populations who experienced pregnancy. Please complete and submit the following table to your BLA by this Friday, July 30, 2021:

Table X: Disposition of Participants 16 Years of age and Older, Safety Populations who Experienced Pregnancy through 13 March 2021

Treatment Group	*BNT162b2 (N=) n (%)*	*Placebo (N=) n (%)*	*Total (N=) n (%)*
Total number of pregnancies			
Withdrawal from study due to pregnancy			
Timing of pregnancy			
Completed 1 dose			
Completed 2 doses			
Completed 3 doses			
Completed 4 doses			
Spontaneous Abortions			
Elective Abortions			
Miscarriage			
Fetal demise			
Birth outcomes known			
Unknown pregnancy outcomes			
Ongoing pregnancy			
Major birth defect			

Please provide the timing of the last dose (BNT162b2), relative to LMP: study vaccination occurred prior to LMP, within 30 days of LMP and >30 days after LMP. This may be expressed as a percentage of total pregnancies.

Pfizer/BioNTech Response

Pfizer/BioNTech have provided the requested information available, including the timing of the last dose (BNT162b2), relative to pregnancy (pregnancy defined as the conception date established by ultrasound, or in the absence of ultrasound, estimated from the LMP), in Table 1 and Table 2 below. Pfizer/BioNTech have not included information on Unknown pregnancy outcomes, Birth outcomes known and Ongoing pregnancy in the programmed tables since these data are not collected as standard in the clinical database (birth outcomes are only collected in the safety database if the site becomes aware of it and updates the pregnancy report). All EDP events logged on the CRF will have the outcome of unknown entered as per the CRF completion guidelines when first logged so it would not give a true reflection of what Pfizer/BioNTech know about the outcomes and similarly it would not give a true reflection of ongoing pregnancies.

At the time of the data cutoff date (13 March 2021), a total of 50 participants who had received BNT162b2 had reported pregnancies, including 42 participants originally randomized to the BNT162b2 group and 8 participants originally randomized to the placebo group who then received BNT162b2 (Module 5.3.5.1 C4591001 Interim Report Body – 6 month update, Section 12.2.4.5.2). In Table 1, the BNT162b2 column includes the 42 participants originally randomized to the BNT162b2 group. In Table 2, the BNT162b2 column includes the 8 participants who were originally randomized to the placebo group who then received BNT162b2.

Table 1. Disposition of Participants 16 Years of age and Older, Phase 2/3, Safety Populations who Experienced Pregnancy through 13 March 2021

	BNT162b2[a] (N=22026) n (%)	Placebo[b] (N=22021) n (%)	Total (N=44047) n (%)
Total number of pregnancies	42 (0.2)	47 (0.2)	89 (0.2)
Withdrawal from vaccination due to pregnancy	5 (0.0)	5 (0.0)	10 (0.0)
Timing of pregnancy			
Completed 1 dose	5 (0.0)	8 (0.0)	13 (0.0)
Completed 2 doses	37 (0.2)	39 (0.2)	76 (0.2)
Timing of last dose relative to pregnancy			
Within 30 days of pregnancy	13 (0.1)	21 (0.1)	34 (0.1)
>30 days after pregnancy	29 (0.1)	26 (0.1)	55 (0.1)
Spontaneous Abortions	3 (0.0)	7 (0.0)	10 (0.0)
Miscarriages	3 (0.0)	5 (0.0)	8 (0.0)
Elective Abortions	0	1 (0.0)	1 (0.0)
Fetal demise	0	0	0
Major birth defects	0	0	0

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary
a. Includes data from Dose 1 through 13 March 2021 for participants who originally received BNT162b2.

Table 1. Disposition of Participants 16 Years of age and Older, Phase 2/3, Safety Populations who Experienced Pregnancy through 13 March 2021

	BNT162b2[a] (N=22026) n (%)	Placebo[b] (N=22021) n (%)	Total (N=44047) n (%)

b. Includes data from Dose 1 to before the first dose of BNT162b2 or through 13 March 2021 for participants who originally received placebo.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (20:15) Source Data: adae Table Generation: 29JUL2021 (12:23)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output
File: ./nda2_unblinded/C4591001_BLA_RR/preg_p23_ge16

Table 2. Disposition of Participants 16 Years of age and Older Who Originally Received Placebo and Then Received BNT162b2 After Unblinding, Phase 2/3, Safety Populations who Experienced Pregnancy through 13 March 2021

	BNT162b2[a] (N=19611) n (%)
Total number of pregnancies	8 (0.0)
Withdrawal from vaccination due to pregnancy	3 (0.0)
Timing of pregnancy	
Completed 1 dose	3 (0.0)
Completed 2 doses	5 (0.0)
Timing of last dose relative to pregnancy	
Within 30 days of pregnancy	7 (0.0)
>30 days after pregnancy	1 (0.0)
Spontaneous Abortions	0
Miscarriages	0
Elective Abortions	0
Fetal demise	0
Major birth defects	0

Note: Human immunodeficiency virus (HIV)-positive subjects are included in this summary
a. Includes data from first dose of BNT162b2 through 13 March 2021 for subjects who originally received placebo and then received BNT162b2 after unblinding.
PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (20:15) Source Data: adae Table Generation: 29JUL2021 (12:23)
(Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output
File: ./nda2_unblinded/C4591001_BLA_RR/preg_p23_xover

Document Approval Record

Document Name:	COVID-19 vaccine July 2021 Response to CBER re Participant Disposition and Pregnancy
Document Title:	COVID-19 vaccine July 2021 Response to CBER re Participant Disposition and Pregnancy

Signed By:	Date(GMT)	Signing Capacity
Maroko, Robert T	30-Jul-2021 18:09:17	Business Line Approver
Perez, John	30-Jul-2021 18:41:56	Final Approval